Introduction
development on the time, cost, quality and regulatory decisions associated with this process • To assess the implications of the new standards for the This report is a distillation of two tandem conferences, definition of evidence of efficacy in the US as they the first entitled ''AAPS, ACCP, ASCPT, FDA Symposium relate to ICH and US regulatory guidances, with special on Clinical Pharmacology: Optimizing the Science of Drug emphasis on the characteristics of confirmatory eviDevelopment'', held in September 1998 in Arlington, dence Virginia, USA, and the second entitled ''5th EUFEPS
• To generate recommendations for the design and analyConference on Optimizing Drug Development: Fast Tracksis of early phase, state-of the-art clinical studies in ing into Human'', held in December 1998 in Wiesbaden, healthy volunteers and patients that allow bridging of Germany. The collective aims of these conferences were:
information from non-clinical to late-phase clinical studies designed to demonstrate safety and efficacy • To prepare a combined summary of the two conferences • To identify critical issues which currently limit drug to facilitate communication of these new ideas for candidate selection and the early phases of human drug optimizing drug candidate selection and early phase development clinical development, as well as to provide a rationale • To explore those modern scientific and technological for the development of future regulatory guidances. innovations which could further improve preclinical and clinical development Drug discovery, lead candidate selection, and pre-clini-• To assess the impact of using modern approaches of cal development are undergoing rapid changes, driven, in clinical pharmacology in the early stages of drug part, by scientific advances in areas such as combinatorial chemistry, molecular and cell biology, high throughput technology, but also by fierce competition and economic *Corresponding author.
forces. As a result, the pressure to accelerate drug discov- 1 The comments and recommendations within this report reflect the ery and development is increasing, especially in the phases personal views of the authors. In particular, the report should not be leading up to and during early human clinical testing, construed as a guidance from either the Food and Drug Administration or the European Medicines Evaluation Agency.
where a clear bottleneck exits. Too often, however, the thrust of change has been on process rather than on formational content across the various phases. In practice, scientific content. The underlying thesis of both conferthe sharing of information across the phases is often ences is that there are numerous opportunities for employsuboptimal. ment of modern pharmaceutical sciences and principles of A summary of the pre-marketing phases of drug declinical pharmacology at every step of the development velopment follows: process to move from an essentially empirical mode to a A. Preclinical Phase (Phase Zero). As part of the drug more mechanistic and predictive one. Doing so will not discovery process, using chemical library profiling and only provide better therapeutic agents with lower risk, but lead compound optimization, the many thousands of can also find failures faster, resulting in a more economical compounds synthesized and tested in high-throughput and informative development program.
biological activity screens are narrowed down to relatively The fundamental concepts which underpin the applicafew compounds that will be evaluated in Phase 1. The tion of clinical pharmacological methods in the drug purpose of the preclinical phase is to further narrow drug development process were laid out in a report published in candidate selection for subsequent evaluation in humans. 1992 from a landmark conference entitled ''Opportunities This is achieved through in vitro studies using human cell for integration of pharmacokinetics, pharmacodynamics, fractions and cultures, whole animal investigations of and toxicokinetics in rational drug development'' (Peck et metabolism, pharmacokinetics and toxicokinetics, the deal., 1992). The major point made then, and now increasvelopment and use of biomarkers thought to provide early ingly accepted, is that the coordinated application of signals of efficacy and toxicity, and considerations inpharmacokinetics (PK) and pharmacodynamics (PD) provolved in developing an acceptable clinical formulation. A vides a rational approach to efficient and informative drug broad, general goal is to integrate knowledge gained from development. The general sequence of scientific and this phase into the decision making process in the design regulatory processes involved in drug development is and conduct of early clinical studies. When it occurs and is depicted in Fig. 1 . These comprise broadly the preclinical bi-directional, this integrative process provides a better or nonclinical phase, sometimes referred to as Phase 0, and understanding of the mechanism of drug action, suggests the three clinical phases, 1,2, and 3 respectively. Postimproved animal models to evaluate drug targets and marketing surveillance (pharmacovigilance) is commonly drug-disease interactions, and helps to design animal referred to as Phase 4. Regulatory reviews generally take experiments which, as second-generation compounds are place just before first administration to human volunteers studied, provide more clinically useful information, predict or patients, at the end of Phase 2, at the end of Phase 3 drug class liability with respect to safety, and generate prior to submission, and then intermittently once a drug is exposure-response relationships for efficacy and safety marketed. Ideally, the entire process from discovery, lead which can be extrapolated from animals to humans. candidate selection through development and registration is B. Phase 1. The goals of this phase, conducted in highly integrated, with overlap and sharing of the inhealthy subjects or, in some cases patients, is primarily to provide information on acute tolerability and safety, dosecommonly overlapping and integrated. The following were plasma concentration profiles, maximum safe doses and the key domains: concentrations, routes of metabolism and elimination and initial estimates of the variability associated with these 2.1. A. In vitro and preclinical studies (Phase 0) measurements. These data are highly relevant to selecting formulation, dose, dosing regimen and route and adminisAn initial objective of the early studies in Phase 0 is to tration in the target patient population. Increasingly, some identify lead compounds, from the myriad produced, that PD data addressing proof of therapeutic concept using a are most likely to have desirable biopharmaceutical, PK, clinically relevant biomarker may be possible during this PD, and clinical properties in humans. High volume phase.
preliminary biological screens, requiring little compound, C. Phase 2. In the first component of this phase (Phase provide relatively coarse information, but allow a subset of 2A), the primary aim is assessment and confirmation of compounds of potential utility to be identified. Using proof of therapeutic concept (efficacy), and affirmation of greater amounts of material in more specific screening acute tolerability, maximum safe dose and plasma conprocedures, more refined and detailed information is then centration, and lack of acute safety issues in patients. In gained on these remaining compounds, to facilitate further the second component (Phase 2B) concurrent aims are selection of only the most promising candidates for further evidence of efficacy and the exploration of dosage subsequent evaluation in humans. The point at which regimens which will be administered to the general target discovery research is said to end and early development population in Phase 3. This exploration of dosing regimens and investigation in humans begins varies from one will include strategies to optimize dosage for individual organization to another. This juncture is often when the subgroups of patients, by identification of relevant patient, decision is made to invest major resources in a compound disease and external factors influencing exposure (PK) and to advance into Phase 1, and to obtain the information exposure-response (PK / PD) relationships. Pharneeded to meet regulatory requirements. macogenetics and pharmacogenomics will play an increasingly greater role in designing and interpreting Phase 2 2.1.1. Prediction of human pharmacokinetic properties studies Significant progress has been made over the last 5 years D. Phase 3. In this confirmatory phase, studies in larger in predicting human absorption and metabolism properties numbers of patients are intended to provide documentation using data from cell-based systems and from whole animal of clinical efficacy and safety, a more complete adverse studies based on the premise that fewer compounds are reaction profile, as well as sources (covariates) and estilikely to be rejected in Phase I because of poor PK mates of variability in dose-response due to both PK and performance. Many of the improvements in prediction PD. This information guides product labeling and stratehave occurred because of the increasing availability of gies for individualized dosing regimens in special populahigh throughput biological screens utilizing human cell tions such as patients with renal or hepatic dysfunction, or lines and enzyme systems, and with the associated relevant the elderly patient.
process rate data incorporated into suitable mathematical Advances in humanized cell based systems, human models. Nonetheless, there is still room for significant transgenic animal models, analytical technologies, compuimprovement. Many approaches are still largely qualitational methods and informatics, combined together with tative, and the goal for the future is to make them more the development of biomarkers and potential surrogate mechanistic and predictive. Among the areas requiring endpoints, modeling and simulation, noninvasive imaging, further development are: and functional genomics, if integrated well, will provide tremendous opportunity to improve and accelerate the drug selection and development processes. Examination and
• A need to improve and increase the number of humanrefinement of the regulatory review process, based on derived in vitro systems, including normal intestinal and sound scientific, legal and ethical principles will help to brain cell lines, hepatocytes, transport systems and encourage such developments.
tissues pertinent to PK and PD and to validate predictions made using these systems. While some validation of the various methodologies may be done in animals, ultimately prediction must be tested against actual 2. Advances and improvements needed organized by human data. development phase
• Greater use of suitably refined whole-body physiologically-based PK models, which use and integrate in vitro The two conferences focused on domains for advances and whole animal data, is needed to facilitate better and improvements that are needed during all phases of prediction (both mean and variability) of human plasma drug development, recognizing that these phases are and tissue concentration-time profiles. This mechanistic approach will facilitate, through scale-up and simulaize the material properties of substances would also tion, exploration of various scenarios affecting exposure facilitate the selection process at an earlier stage. (e.g. disease, regimens, interactions) likely to arise
• An improved quantitative understanding of the interacduring drug development. tions between excipient and compound would greatly • Coupling of PK with in vitro / in vivo PD responses at help in selecting the appropriate formulation and reducthe preclinical stage. This would contribute to drug ing subject-by-formulation interactions and intrasubject selection and help define the target plasma and tissue variability. concentration-time profiles, as well as the appropriate
• Improved methods are needed to calculate the likely route and rate of administration likely to achieve maximum bioavailable dose, a critical parameter that optimal therapeutic response.
helps determine the maximum possible unit dose • Better and earlier studies of plasma protein binding.
strength of the formulation and dosage regimen. Open Protein binding is a major determinant of the pharminded consideration of all possible routes and rates of macokinetic features of a compound. Currently, methadministration (including transdermal, intranasal, inhaods to determine protein binding are relatively tedious lation, etc.), novel drug delivery systems, and formulaand time-consuming. Better and more rapid screening tion techniques (e.g. nanoparticles, liposomes, etc.) is methods would facilitate this information being availadvised in order to optimize availability of the new drug able at an earlier time in the drug selection process.
at its site of action, while minimizing effects at undesir-• Better understanding of structure-PK relationships.
able sites. This is needed to help the medicinal chemist to more efficiently design molecules with the optimal biological 2.1.3. Preclinical efficacy and safety data to facilitate properties. Existing computational methods to relate rapid entry into humans structure to ADME and PK profiles are embryonic and Preclinical efficacy and safety assessment strategies to significant improvements are needed if these are to be support fast tracking into humans are undergoing signifiof greater value.
cant changes driven by advances in molecular biology and • More robust bioinformatic software. This is critical for more mechanistic understanding of drug action. And, while capturing, organizing, and interrelating data among in vitro cellular systems (cell lines, subcellular fractions, disciplines. A vast amount of data are produced from etc.) are increasingly used, it is strongly recommended that high throughput screens of ADME and PK processes, traditional animal models should continue to be employed. and these must be readily accessed throughout drug This is because animal studies often provide important development.
insights at an early stage into PK-PD relationships and • More precise and informative PK (and PD) data. The optimal dosing regimen strategies, as well as allowing quality and quantity must increase progressively over evaluation of potential risks in teratology, reproduction, time, from lead candidate selection through dosing and cardiac and hepatic toxicity. Animal models allow decisions made at all phases of drug development.
evaluation of drug targets as well as target / disease interactions, and can be used to study concentration-response-2.1.2. Prediction of biopharmaceutical and formulation time relationships associated with a variety of dosing properties strategies which cannot be readily undertaken in humans. Many a developmental program falters because a comRecent advances in proteomics and pharmacogenomics pound has poor biopharmaceutical properties, such as low promise to provide an opportunity to establish better intestinal permeability and poor absorption, or has probpredictive biomarkers and surrogate endpoints for early lems with dissolution of the compound from the pharmaindication of delayed-onset and / or long-term efficacy and ceutical formulation, leading to low and highly variable safety outcomes. Preclinical relationships between expobioavailability. The challenge is to reduce or remove these sure and biomarkers will also provide scientific support for limitations at the preclinical stage and if possible have the the rapid assessment of proof of concept (efficacy and ''optimal'' formulation at the time of entry into humans, or safety) in humans. alternatively rapidly gain the necessary information to
There is a critical need to develop databases that permit achieve this objective during Phase 1. The issues and integration of in vitro and in vivo data from functional improvements needed here are:
toxicology and exposure-response information, and that facilitate toxicokinetic-toxicodynamic mathematical and / or physiological modeling to provide a ''bridge'' to assess the • Better computational methods, determined by critically range of dosage regimens proposed for clinical assessment examining structure-function relationships between of pharmaceuticals in healthy human subjects and / or physicochemical properties, which could substantially patients. These databases could also be used in both a reduce the number of compounds that need to be tested.
retrospective and prospective analyses of safety and tox-• Development of nanotechnology approaches that reicology data to provide direction for future changes in quire only minute quantities of compound to characterpreclinical safety testing.
Some further areas needing progress in preclinical value and progress in the informativeness of Phase 1 assessment include: studies, there are areas for further improvement and utility.
2.2.1. Pharmacokinetic-pharmacodynamic assessments. Two significant differences exist in characterizing PK • Earlier exploration of genomically identified novel and PD processes. One is specificity. With modern anatargets involved in the pathogenesis and progression of lytical instrumentation, specific PK data can be obtained disease to identify compounds and facilitate informed for each chemical species independently, but many comdecisions at the outset of the drug development process.
pounds in the same class may evoke the same or similar • Evaluation of a two-stage testing paradigm in which a PD responses. The second is linearity. Most PK processes single tracer dose human clinical trial, justified by a (absorption, distribution, and elimination) are not saturable single dose animal toxicology study, serves as a guide in the pharmacologic or therapeutic dose range. Accordto animal species and dosage regimen selection for ingly, the PK of most compounds are linear or dosemore extensive animal multidose and carcinogenicity independent. In contrast, nonlinearity of the PD response studies. The tracer dosage would be sub-pharmacoas a function of dose or concentration is normal. logical, using cold or radioactive or stable isotope A few companies have reported that PK specificity and labeled tracer drug doses, if bioanalytical methods are linearity is being used to advantage in preclinical screening available, to enable safe human exposure.
by the use of ''cassette dosing''. Cassette dosing involves • Continued discussions of the use of cassette dosing in the simultaneous administration of a mixture of up to 10 animals and the development of the screening IND for and occasionally more compounds, in order to rapidly human testing, neither of which are routine or feasible identify those compounds with desirable PK profiles. under the current preclinical safety testing programs.
These latter compounds are then taken further into PD screens, which requires each compound to be evaluated separately.
B. Phase 1 studies
Based on the above considerations, there is an argument for exploring the division of Phase 1 into two phases: Historically, the primary objective of Phase 1 first-inman studies was to assess acute tolerability and safety, and to define the maximum tolerated dose (MTD). Subsequent-
• Phase 1a. The objective of this phase would be to ly, with the advent of suitable bioanalytical methods, the assess preliminary PK and especially metabolic propobjective(s) were expanded to characterization of the erties. This phase would involve the administration of a biopharmaceutical performance, PK and metabolic profiles, small dose below that which would provide any and the relationship between plasma concentrations of drug measurable pharmacological or clinical effect, prefer-(and metabolites) and desirable and undesirable effects. As ably in solution, of either a single compound or currently practiced, Phase 1 often includes all studies possibly a mixture of compounds given by the desired involving healthy subjects or patients who are not the route. If more than one compound is given simulintended population to receive the drug, e.g., patients with taneously, it is assumed that the PK and metabolism of renal impairment. These include food and drug interaction each compound be independent of the other compounds studies, radiolabelled mass balance studies, dose proporadministered, based on animal or in vitro data. In some tionality studies, as well as studies to assess effects of instances, this might require confirmation. Only comvarious diseases, and various formulations and comparapounds that had desirable PK properties would be tive bioavailability. In the past bioanalytical work was evaluated further. PK and metabolism information from invariably performed some time after completion of the this investigation could also be fed back to the discovacute tolerability study, whereas today the design is ery and preclinical toxicology teams for further optimiincreasingly more adaptive, with analysis performed durzation criteria of candidate lead compounds. It is ing the study to guide subsequent dosing within the same envisaged that only small quantities of compound or a subsequent study.
would be needed at this stage. The information gained from Phase 1 studies is some-
• Phase 1b. The objectives of this phase would be to times used to select the relevant animal species and the assess acute tolerability and detailed PK, and the degree of systemic exposure needed for future toxicologibiopharmaceutical characteristics, as is done currently. cal, teratogenic and carcinogenicity assessments. Phase I
• This two-stage (phase 1A and 1B) argument is based on results are also used to guide the design of Phase 2 studies, scientific credibility and efficiency gains, but has clear particularly the dose size and range, frequency and route of ethical implications. Some ethical and practical advanadministration, and appropriate dosage form, and predict tages of this division of Phase 1 are: drug exposure in certain patient groups defined by both
• It would minimize the possibility, which exists currentintrinsic (e.g. age, gender, disease) and extrinsic (e.g. ly, of volunteers being unnecessarily exposed in high drugs) factors suspected to influence exposure. Despite the dose tolerability studies to new chemical entities with provements needed for fuller utilization of this approach poor PK properties, which are unlikely to be developed are implementation of sparse sampling paradigms for further.
animal PK experiments, and expanded demonstrations of • It could reduce the number of animals needed in the the technique with biomarkers that are measurable in both preclinical screening programs, as well as reduce the animals and humans; optimally these biomarkers would be amount of compound needed to be synthesized, for non-invasive. compounds dropped at Phase 1a.
• It would provide a rich human database for developing 2.5. Biomarkers /surrogate endpoints relationships between in vitro and physicochemical data and human PK data, which ultimately can be used in When clinical effects of the new drug are not easily computer models to evaluate drug development measured or are slow to develop, POC trials are greatly scenarios in situ. If the compounds were given both enhanced by the use of biomarkers that serve as rapid and orally and intravenously, this development could be readily measured effects that are causally related to clinical extended to refining absorption and biopharmaceutical effects. Panels of biomarkers may also provide greater properties, prior to evaluating formulation issues.
prediction of delayed toxicity. New classes of biomarkers have been identified for safety assessments based on 2.3. C. Phase 2 studies: proof of concept emerging knowledge of genomics and proteomics, such as damage-specific inducible genes, biochemical markers of Assessment of ''Proof of Concept'' (sometimes called cell death, chemokines / surface markers of cell infiltration, proof of principle) may have multiple meanings to drug tissue-specific markers of cell integrity, signaling moledevelopment scientists, ranging from preclinical in vitro or cules as functional markers, and other disease progression animal investigations that establish a postulated pharmacomarkers. It is important to distinguish between a biomarker logical action to human trials that demonstrate a pharmacoand a surrogate endpoint. To avoid surprises, proposed logical or clinical effect predicted from preclinical experisurrogate endpoints are suspect until fully validated. ments or other human data. A precise definition of the Concern about accepting new surrogate endpoints for drug usual ''Proof of Concept'' human study in Phase 2 of drug registration has been expressed within the pharmaceutical development proposed by 5th EUFEPS Conference parindustry and by regulatory authorities unless they are ticipants is ''a human trial that provides scientifically appropriately linked to clinical endpoints using credible sound evidence supporting the postulated effect(s) of a new study designs and data analysis procedures. As a result, therapeutic drug product, where 'effects' may be relevant biomarkers are frequently ignored or abandoned after pharmacological action or a change in disease biomarkers, Phase 2 as attention is turned to clinical outcome measures. established surrogate endpoints, or clinical outcomes, and Recently, NIH and FDA have encouraged advancement of may be beneficial and / or toxic in nature''. Because the biomarker and clinical endpoint concepts, by proposing Phase 2 Proof of Concept clinical trial (abbreviated POC strict definitions, and a statistical framework for validation hereafter), is often used for ''go / no-go'' (investment) (Atkinson et al., submitted) . decisions, it has become one of the most critical trials in Improvements needed to expand the use of biomarker / the development program. While many advances in this surrogate concepts include: phase have been made, particularly by combining PK with PD, there is still considerable room for improvement.
Some candidate procedures for accelerating of proof of • practical procedures for in-development investigations concept trials include the following: using biomarkers (particularly for novel mechanisms of action) that generate evidence for linkage with clinical 2.4. Whole animal, mechanism-based, PK-PD modeling endpoints to forecast human PK-PD
• model-based linkage between disease and pharmacological mechanisms or clinical endpoints This preclinical study, discussed in Section I.A and I.C
• a shift in emphasis from criterion (empirical) assessof this report, is reiterated here due to the importance of ment to mechanistic assessment using biomarkers. employing early physiologically based whole animal PK-PD modeling as one of the frameworks for rational and 2.6. Examples of accelerating proof of concept and drug efficient drug development. Here, ''PD'' refers to biodevelopment markers, including physiological, laboratory, and anatomical (imaging) measurements. Application of this approach Contemporary clinical drug development is changing. to dose selection and escalation in early human trials has a This statement is based on a comparison of the current sound, established conceptual basis, having been demonsituation to the period up to 1995, when a typical NDA had strated in animals and humans for more than six classes of a 7-year clinical development phase, up to 60 clinical trials antineoplastic drugs (Collins et al., 1990) . Among imand over 3000 subjects. The impact of early intensified clinical pharmacology on subsequent drug development is 1. A scientific and clinical basis by which safety concerns specifically impacting in the selection of dose and dosage were alleviated regimens for Phase 1, Phase 2 and Phase 3 studies, in 2. Avoidance of a specific clinical trial to assess dexaguiding dosage adjustments in special populations, in methasone's effects on taxotere clearance selecting relevant animal species for toxicology, in making 3. Accelerated approval of the drug for market access go / no-go decisions using POC trials, and in deciding to 4. Provision of key information in the package insert. discontinue drug development. There has been an estimated time savings of 2-24 weeks in Phase 1 and 4-72 2.6.3. Ritonavir weeks in Phases 2 / 3 in recent examples of the value of PK / PD studies played a key role in the accelerated clinical pharmacology in the drug development process at approval of this and other antiviral drugs for market access one major pharmaceutical company (Reigner et al., 1997) .
for the treatment of AIDS patients. The use of efficacy PD There are numerous examples of strategic use of PK / PD in surrogate endpoints for efficacy (CD4, viral load) allowed deriving key information about the clinical pharmacology decisions to be made earlier in time, and to be based on of the drug. The following three examples illustrate well relatively smaller numbers of patients than would otherhow application of PK / PD modeling using biomarkers wise be the case. However, it was important here, as is and / or surrogate endpoints accelerated drug development.
generally the case, that the PK / PD data was robust, with a complete understanding of the biological plausibility of the 2.6.1. Remifentanil surrogate endpoint. In the case of ritonavir, and antiviral This example illustrates the use of the EEG as an drugs in general, surrogate endpoints proved of benefit in: efficacy biomarker in the development of new opioid anesthetics, such as remifentanil (Egan et al., 1993; Glass et al., 1993) . In particular, ''fingerprinting'' of new drugs 1. Assessing the stage of disease or rate of change in during the investigational development phase, using high disease status or severity resolution PK / PD approaches, allowed rational decisions 2. Assessing the effects of therapeutic intervention about the efficacy, safety, as well as the differential 3. Predicting clinical benefit. profiling of the new compound compared to marketed drugs in the same chemical or therapeutic class (Shafer 2.7. Clinical trial design and analysis and Varvel, 1991). The derived benefits of this approach included:
To effectively utilize tools of modern clinical pharmacology, such as population PK / PD analysis and PK / PD models, clinical trial designs or paradigms should be 1. Development of PK / PD relationships that facilitated considered that are appropriate to the information requirethe go / no-go decision (POC) ment at hand. Depending on the phase of drug develop-2. Application of PK / PD early in Phase 1, along with ment, the goals of clinical trials may be confirmatory (late effect site computer models, provided nearly optimal phase) or explanatory (early phase). Study designs with a dosages for Phase 2 and Phase 3 as well as a greater confirmatory perspective include: understanding of onset and offset of the anesthetic agent.
• intent to treat 2.6.2. Taxotere
• fixed dose and dosing regimen designs with analysis of In this case, the value of nonlinear mixed effects average results over time, and modeling of dose-PK-PD relationships using sparse plas-
• on-drug analyses ma samples was demonstrated (Bruno et al., 1998) . Through this analysis, the plasma clearance was shown both to be significantly decreased in patients with hepatic
The features and results of these study designs include a impairment and hepatic function was a significant predictor goal of gross hypothesis testing, the use of a null model, of clinical neutropenia. Furthermore, PK / PD analysis treatment for analysis as assigned, relatively few assumpidentified patients at risk for neutropenia, and justified the tions, low study power, little ability to interpolate / extraposubsequent safety re-analysis of the clinical database to late or to individualize therapy, and a high degree of address questions posed by both sponsor and regulatory certainty. authorities, that allowed the sponsor to confirm the safety In contrast, the features and results of explanatory study profile of the drug without waiting for Phase 3 data. The designs include a goal of estimation, a causal or mechanis-PK / PD data also provided the basis for the labeling as tic model, treatment for analysis as treated, many assumpwell as usage recommendations for patients based on liver tions, high study power, greater ability to interpolate / function tests. In this case, population PK / PD studies extrapolate and a relatively low or high degree of certainty provided many advantages including:
depending on assumptions.
Attempts should be made to build an explanatory or The challenge in accelerating drug development is to do ''learning'' perspective into study designs and data analyso without lowering scientific and clinical standards. sis that have a confirmatory focus. Some examples of these Experience with accelerated development of antiviral drugs study designs and methods of data analysis include: has demonstrated that it is possible to combine study designs and types of efficacy evidence to achieve accelerated development without compromising quality.
• modified intent to treat 2.9. Learning and confirming • instrumental variable analysis • adaptive strategies
The application of good clinical pharmacology to trial • dose or concentration response.
design and analysis, as evidenced in the remifentanil, taxotere and ritonavir examples, raise the question of when Modifications of traditional confirmatory studies serve to a model-based analysis can contribute to regulatory deciaddress problems associated with confirmatory trials. For sions to allow market access. The main issue in this regard example, with antiviral drugs, pharmacodynamic measureis the role of explanatory versus confirmatory analysis ments or surrogate endpoints could be designed into intent models (Sheiner, 1997). The features of explanatory to treat clinical trials to: (1) evaluate initial response and to models include the goal of estimation, and the model is identify non-responders before the end of the trial, and usually causal or mechanistic in nature. Explanatory removing them, (2) identify the time period of response models are often used for traditional PK / PD studies as following fixed dose administration before assessing cliniconducted in Phase 1, and to determine optimal dose and cal outcomes, and (3) establish criteria for loss of response dosing regimens in Phase 2B. Explanatory models, because over time in the trial in order to assess the duration of they involve various assumptions to generate the model, response.
are used when the certainty required is relatively low and Population PK / PD has been proposed as an approach to the results are not being used alone for decisions about accelerating drug development and maximizing the knowlmarketability. However, the results of these models may be edge gained from confirmatory trials. Its usefulness is most robust because many factors are considered and usually evident when it is clear what target patient covariates are with high power. Explanatory models may be especially considered pertinent for dosing and / or for labeling. It is useful in making label language decisions or in allowing also important to determine when and how to incorporate a interpolation or extrapolation within or beyond the results population analysis of PK and PD measurements into a of a given clinical trial, and in some cases as supportive drug development plan. A priori identification of special evidence for a single trial using confirmatory models. populations at risk who may require dosage adjustments is Confirmatory models have as their most important goal a challenge to drug developers, and no one approach will the testing of the null hypothesis of no difference between fit all situations. The use of adaptive designs deserves two treatments. With strictly empiric, confirmatory models greater consideration. Dose and concentration response there is greater certainty because the assumptions are few, trials provide highly informative information relevant to and this is often required in certain decision making dose selection, especially in Phase 2B.
situations, especially by drug regulators. For example, confirmatory models are used by industry in Phase 2 to 2.8. Accelerating the drug development process confirm efficacy in small patient populations, and in Phase 3 by regulators to confirm safety and efficacy in large Implementation of modern clinical pharmacology in patient populations in the context of clinical use. In some drug development also accommodates practical process cases, confirmatory models have an explanatory compostrategies to accelerate drug development. With the emnent. phasis on acceleration, there are only a limited number of For example, as discussed earlier, collection of sparse options. They include:
numbers of plasma concentrations during a confirmatory trial, followed by a population analysis of plasma drug levels, provides an opportunity to learn about patient covariates, such as intrinsic (e.g., gender) and extrinsic • telescoping or overlapping phases of clinical develop-(e.g., coadministration of drugs) factors that affect pharment; macokinetics (PK) and possibly explain differences in • intensifying efforts in a given phase of drug developclinical responses related to variability or changes in PK. ment;
• combining multiple objectives and efforts, e.g., combin-2.10. Further improvements and utility ing PK goals with clinical goals in a given trial • simplifying clinical programs and shortening timelines;
Motivated by the urgent need to drastically improve the • skipping or postponing studies, which is the accelerated efficiency and informativeness of drug development proapproval paradigm.
grams even further, pharmaceutical developers are seeking clinical trial designs, analysis and interpretation. Strategies ways to optimize each clinical trial by applying novel for increasing awareness and receptiveness of these apapproaches to the planning and evaluation of clinical trials.
proaches in the regulatory sector are also needed. Among the most promising new ideas are simulation of trials and development programs, novel statistical ap-2.10.3. Genome-based subject selection proaches to trial designs, and genome-based subject selecAdvances in pharmacogenetics and genomics may imtion.
prove the power of human trials by using techniques for trial subject selection on the basis of genetic profiles that 2.10.1. Modeling and simulation improve diagnostic certainty or optimize pharmacogenetic Computer assisted modeling and simulation (M&S) of acceptability. Practical pharmacogenetic profiling techclinical trials is a rapidly advancing approach for optiminiques are currently under development (e.g. chip-based zation of clinical trial designs that can successfully achieve gene screens for human drug metabolizing enzymes) while the trials' scientific and therapeutic goals. The modeling the impending full sequencing of the human genome employs sound pharmacokinetic and pharmacodynamic promises additional techniques for identification of genetic data derived from animal or early human studies. Virtual factors that affect efficacy or safety of new drugs. Adtrials are run using proposed clinical trial designs and real vances in the understanding of the genetic basis of disease world trial attributes (dropouts, variable compliance, vari- will also result in new leads in phenotyping of disease ous sources of known and random variability, etc. The following concepts could also improve overall (often simple) design with minimal assumptions. Although clinical drug development. known to be inefficient and minimally informative, fixed dose and duration, parallel group designs have dominated.
2.11.1. Minimum dose for satisfactory effect (MDSE) Novel statistical approaches have been proposed that aim A critical goal of Phase 2 is identification of a dosage to achieve greater efficiency in learning and confirming regimen that provides a high probability of successful trials, by employment of adaptive clinical trial designs and confirmation in Phase 3 that the compound is safe and pharmacologically informed cross-over designs. In the effective. Frequently, dose-finding for Phase 3 has been limit, such approaches could compress trials in size and imperfect, depending upon the sophistication of the doseduration, or even collapse development phases such that response investigations undertaken, ranging from unintraditional goals of Phases 2 and 3 are achieved in a single formed ''ball-park'' guesses to scientifically-based optimal adaptively designed clinical trial. Despite these potential dose identification. The traditional goal of Phase 2 dosebenefits, adaptive and cross-over designs are currently finding has been to identify Maximum Safe Dose (MSD). underutilized. Improvements needed include better training This has been justified in oncology on medical, ethical and of statisticians in pathophysiology and pharmacology so statistical grounds for maximizing the power in a simple they can couple knowledge of modern pharmacology with placebo controlled trial. The MSD strategy, nevertheless, has often resulted in testing (even marketing) of excessivecians is critical to achieve the most valued results. Major ly high dosages that ultimately cause safety problems, and obstacles in communication can occur where there is there are many examples of this problem. To address this handoff of research data between disciplines, so there is a problem the concept of the Minimum Dose for Satisfactory critical need to improve data collection procedures, to Effect (MDSE) is suggested. While currently available allow exchange of data among different databases, and to dose-response trial methodology exists for discovery of the archive data in a manner which allows integration with MDSE, it is often not applied or utilized in creating the new data from current development programs.. These are drug label. A potential consequence of this to the drug prerequisites to optimizing corporate decision making, and developer is a reduction in dosing that occurs after designing focused, information-rich clinical studies with marketing and resultant reduction in sales or the need to multiple objectives. develop an additional dosing form. Needed developments to establish this concept include practical dose-response 2.11.5. Regulatory initiatives designs for finding the MDSE in Phase 2 and regulatory International and domestic regulatory initiatives receptivity and encouragement for identification of uninevitably have a substantial impact on drug development. studied MDSE via interpolation from dose-response Some important current initiatives include: modeling. Again, examples of interpolation already exist in the regulatory environment.
• provides an alternative to the efficacy standard of two for the new drug product and the research goals and adequate and well-controlled clinical trials, using PK / approaches of the sponsor takes the form of the Inves-PD studies, tigator's Brochure (IB) and the draft label. The IB, which
• codification of fast track, accelerated approval regulashould be constantly updated, provides a running summary tions, of the entire knowledge base on the new drug that
• good guidance practices and FDA's Medical Policy promotes awareness and knowledge by all members of the Coordinating Committee (Clinical Pharmacology Secproduct development team. Consideration should be given tion) guidances, to maintaining the IB in an online format to facilitate International Conference on Harmonization (ICH) updating and review by investigators.
guidances and in particular, the Common Technical Document (CTD) for efficacy.
Training of ethical committees
Fastracking new drug development requires novel strategies and techniques that may be unfamiliar or even 3. Conclusions uncomfortable for traditional ethical committees. Training of ethical committees on advances in drug development Advances in a whole host of technologies, together with science, to increase their receptivity to novel approaches, is a much better understanding of the way in which comrecommended.
pounds are handled by the body and how they act to produce their effects, is facilitating the better and more 2.11.4. Organizational behavior rational design of new therapeutic agents and their preBeyond scientific strategies and tactics, organizational clinical and clinical testing. However, pressure on rebehavior and culture can profoundly influence the success sources and time demands ever more efficient approaches. of drug development. Better communication across all
The authors believe that this will best be achieved by the disciplines is needed to help guide drug development more increasing integration of information from all phases of efficiently and informatively with regard to strategic drug selection and development, through the application of decision making. For example, to become more contributmodeling and simulation methodologies, thereby improvory, clinical pharmacologists should get involved earlier in ing the informational content while reducing the amount of the drug development process, focusing on a better underexperimentation required. standing of preclinical and clinical drug metabolism, scaling of preclinical PK data to humans, and identification of biomarkers to incorporate into the drug development
